Survival after nonmyeloablative as compared with myeloablative conditioning. (A) Kaplan-Meier estimates of overall survival for cohorts of age-matched patients who underwent nonmyeloablative (n = 44) and myeloablative (n = 52) HSCT between March 2000 and September 2001 for hematologic malignancies and renal cell carcinoma. (B) Probabilities of death with manifestations of GVHD under treatment in the nonmyeloablative and myeloablative groups.